Clinical trials landscape in a lower-middle-income country (Pakistan).
| Autor: | Mumtaz H; Clinical Research Associate, Maroof International Hospital, Islamabad, Pakistan.; Public Health Scholar, Health Services Academy, Islamabad, Pakistan., Haider SMA; BMY Health, Lahore, Pakistan., Neha F; Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan., Saqib M; Khyber Medical College, Peshawar, Pakistan., Nadeem A; Dow University of Health Sciences, Karachi, Pakistan., Seikha Z; Dow University of Health Sciences, Karachi, Pakistan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical and translational science [J Clin Transl Sci] 2023 Dec 10; Vol. 8 (1), pp. e7. Date of Electronic Publication: 2023 Dec 10 (Print Publication: 2024). |
| DOI: | 10.1017/cts.2023.701 |
| Abstrakt: | In recent times, there have been calls from within the developing nations for increased ownership by governmental research bodies and universities of the priority research setting and research that aligns with national health strategies. This is a review paper of the studies that have been published on clinical trials in developing countries, with a focus mainly on Pakistan. The literature review used online databases such as PubMed, Scopus, and Google Scholar, World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov trial registries to search for clinical trials conducted in Pakistan between January 2000 and December 2022 and analyzed. The results revealed that clinical research in Pakistan is hindered by a number of barriers, including a lack of funding, skilled personnel, and regulatory issues. Lack of funding is a common obstacle, and the majority of funding for clinical trials originates from Western countries or pharmaceutical companies established in the West. In conclusion, clinical studies in developing countries, especially in Pakistan, are hindered by a plethora of barriers, and to improve the current state, increasing funding, streamlining ethical approval procedures, simplifying regulatory systems, addressing cultural and religious concerns, and participating in global efforts to bridge the gap in health-based research are crucial. Competing Interests: There are no funders to report. (© The Author(s) 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|